News ReleasesProtox Modifies Terms Of Share Purchase Warrants Vancouver, British Columbia, October 25, 2007 – Protox Therapeutics Inc. (TSX-V:PRX), a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases, today announced that the Company’s Board of Directors has approved changes to the terms of two sets of common share purchase warrants (“warrants”) issued as a result of a private placement completed during November 2005. The warrants issued on November 4, 2005 for the first tranche of the private placement and on November 17, 2005 for the second tranche of the private placement are now transferable. These warrants entitle the holder to purchase one common share of Protox at a price of $0.65 for a period of 24 months from the closing dates of the first and second tranches of the private placement. A warrant holder wishing to transfer warrants must complete a transfer form that can be obtained from the company. While the warrants will be transferable they will not be listed for trading on the TSX-V and any transfer made must be in compliance with applicable securities legislation. About Protox NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information contact: James Beesley Michael Moore |
2006 Protox Therapeutics Inc. All Rights Reserved. Legal Disclaimer. |